BPC-157

Featured

Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157, PL 14736

A synthetic pentadecapeptide derived from human gastric juice with remarkable tissue-healing properties.

Overview

BPC-157 is a synthetic 15 amino acid peptide derived from a portion of the human gastric protein BPC. First isolated from human gastric juice, this peptide has demonstrated significant cytoprotective and healing properties across multiple tissue types in preclinical studies.

Mechanism of Action

BPC-157 upregulates growth hormone receptor expression and modulates the nitric oxide system, promoting angiogenesis through VEGF upregulation. It promotes the FAK-paxillin pathway crucial for cell migration and wound healing.

Pharmacokinetics

BPC-157 demonstrates remarkable stability in gastric juice, maintaining activity for over 24 hours. Shows activity at nanogram to microgram doses.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Systemic Protocol

Dose

250-500 mcg

Frequency

1-2 times daily

Duration

4-12 weeks

Subcutaneous for systemic healing

2

Local Injection

Dose

200-300 mcg

Frequency

Once daily

Duration

2-4 weeks

Near injury site for localized effect

3

Oral Protocol

Dose

500 mcg

Frequency

Twice daily

Duration

4-8 weeks

For GI-specific applications

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Synergistic healing

Synergy: TB-500 promotes cell migration while BPC-157 accelerates tissue repair

Rationale: Enhanced tissue remodeling

Synergy: GHK-Cu promotes collagen synthesis complementing BPC-157

Research Areas

Tendon/Ligament HealingGastrointestinal ProtectionMuscle Injury RecoveryNerve RegenerationBone Healing

Key Research Findings

  • 1Accelerated healing of transected Achilles tendons in rat models by 72%
  • 2Demonstrated cytoprotection against NSAID-induced gastric lesions
  • 3Promoted angiogenesis and granulation tissue formation
  • 4Showed neuroprotective effects in traumatic brain injury models

Side Effects & Contraindications

Reported Side Effects

  • Injection site irritation (rare)
  • Generally well-tolerated

Contraindications

  • Active malignancy (theoretical)
  • Pregnancy (insufficient data)

Safety Considerations

No significant toxicity observed in animal studies at doses up to 10 mg/kg. Human safety data is limited.

Storage Requirements

Store lyophilized at -20C. Reconstituted stable at 2-8C for 14 days.

Scientific References

Quick Reference

Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Weight
1419.53 g/mol
Half-Life
Not fully characterized in humans
Bioavailability
High oral stability; systemic varies by route
Research Stage
clinical phase 2
Administration
Subcutaneous, intramuscular, or oral